$2.52T
Total marketcap
$187.5B
Total volume
BTC 50.06%     ETH 15.91%
Dominance

IVERIC bio ISEE Stock

39.48 USD {{ price }} 0.000000% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
5.3B USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

IVERIC bio Price Chart

IVERIC bio ISEE Financial and Trading Overview

IVERIC bio stock price 39.48 USD
Previous Close 38.14 USD
Open 38.2 USD
Bid 0 USD x 900
Ask 0 USD x 800
Day's Range 38.07 - 38.45 USD
52 Week Range 8.95 - 38.99 USD
Volume 2.52M USD
Avg. Volume 3.72M USD
Market Cap 5.3B USD
Beta (5Y Monthly) 1.108098
PE Ratio (TTM) N/A
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 39.18 USD

ISEE Valuation Measures

Enterprise Value 4.75B USD
Trailing P/E N/A
Forward P/E -29.33588
PEG Ratio (5 yr expected) 0.54
Price/Sales (ttm) N/A
Price/Book (mrq) 11.055811
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -20.765

Trading Information

IVERIC bio Stock Price History

Beta (5Y Monthly) 1.108098
52-Week Change 308.82%
S&P500 52-Week Change 20.43%
52 Week High 38.99 USD
52 Week Low 8.95 USD
50-Day Moving Average 34.9 USD
200-Day Moving Average 24.3 USD

ISEE Share Statistics

Avg. Volume (3 month) 3.72M USD
Avg. Daily Volume (10-Days) 3.37M USD
Shares Outstanding 137.98M
Float 137.01M
Short Ratio 2.44
% Held by Insiders 0.65%
% Held by Institutions 109.36%
Shares Short 15.07M
Short % of Float 10.99%
Short % of Shares Outstanding 10.91%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -29.63%
Return on Equity (ttm) -55.023%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -117012000 USD
EBITDA -228890000 USD
Net Income Avi to Common (ttm) -222904000 USD
Diluted EPS (ttm) -1.77
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 599.92M USD
Total Cash Per Share (mrq) 4.35 USD
Total Debt (mrq) 97.76M USD
Total Debt/Equity (mrq) 20.49 USD
Current Ratio (mrq) 15.532
Book Value Per Share (mrq) 3.476

Cash Flow Statement

Operating Cash Flow (ttm) -176852000 USD
Levered Free Cash Flow (ttm) -97539128 USD

Profile of IVERIC bio

Country United States
State NJ
City Parsippany
Address 8 Sylvan Way
ZIP 07054
Phone 609 474 6755
Website https://ivericbio.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 163

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Q&A For IVERIC bio Stock

What is a current ISEE stock price?

IVERIC bio ISEE stock price today per share is 39.48 USD.

How to purchase IVERIC bio stock?

You can buy ISEE shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for IVERIC bio?

The stock symbol or ticker of IVERIC bio is ISEE.

Which industry does the IVERIC bio company belong to?

The IVERIC bio industry is Biotechnology.

How many shares does IVERIC bio have in circulation?

The max supply of IVERIC bio shares is 134.31M.

What is IVERIC bio Price to Earnings Ratio (PE Ratio)?

IVERIC bio PE Ratio is 0.00000000 now.

What was IVERIC bio earnings per share over the trailing 12 months (TTM)?

IVERIC bio EPS is 0 USD over the trailing 12 months.

Which sector does the IVERIC bio company belong to?

The IVERIC bio sector is Healthcare.

IVERIC bio ISEE included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD